CIN-102
OVERVIEW:
CinDome’s CIN-102 (deudomperidone) is a molecular improvement of domperidone, a frequently prescribed first line therapy for nausea, vomiting, and gastroparesis outside of the United States. In part due to safety concerns around QT prolongation, domperidone is not approved in the US. CIN-102 was developed as a new chemical entity by the formulation and pharmacology team at CinRx to alter the PK profile for sustained efficacy while significantly reducing cardiac liability.
CinDome has progressed CIN-102 from concept into Phase 2 with favorable PK profile, a negative TQT study, and promising effect on gastric emptying and improvement of nausea and vomiting in subjects with gastroparesis.
1. Rey E, Choung RS, Schleck CD, Zinsmeister AR, Talley NJ, Locke GR 3rd. Prevalence of hidden gastroparesis in the community: the gastroparesis “iceberg”. J Neurogastroenterol Motil. 2012 Jan;18(1):34-42
2. Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225-1233
GASTROPARESIS
Metrics:
12-16 million patients in the US have symptoms of gastroparesis
>$4B annual prescription market in the US
Currently no chronic treatments available
REASONS
TO BELIEVE
- CIN-102 does not cross the blood brain barrier,unlike metroclorpramide, which is currently the only FDA-approved drug for gastroparesis and carries a black-box warning for tardive dyskinesia
- 20-50% patients with gastroparesis use off-label treatments or go untreated, leaving a major unmet medical need and significant therapeutic development opportunity
- CIN-102-121 Phase 2 study is signaling strong safety and efficacy
- A potential for GERD indication is being explored, which could extend the application of CIN-102 into an additional population with a large unmet medical need
